- Home
- RAYA vs CVKD Comparison
RAYA vs CVKD Comparison
Compare RAYA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RAYA | CVKD |
|---|---|---|
| Founded | 2019 | 2022 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 20.7M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RAYA | CVKD |
|---|---|---|
| Price | $4.16 | $7.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 28.1K | ★ 81.7K |
| Earning Date | 04-17-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,101,325.00 | N/A |
| Revenue This Year | $20.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $3.13 | $6.75 |
| 52 Week High | $736.99 | $22.90 |
Technical Indicators
Market Signals| Indicator | RAYA | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 46.80 | 37.10 |
| Support Level | $4.20 | $6.75 |
| Resistance Level | $4.50 | $7.75 |
| Average True Range (ATR) | 0.47 | 0.96 |
| MACD | -0.04 | -0.18 |
| Stochastic Oscillator | 17.77 | 12.87 |
Price Performance
Historical ComparisonAbout RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from four products namely inverters, chargers, power bank, and gasoline generators. The company generates the majority of its revenue from Inverters. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.